C4 Therapeutics/$CCCC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- Ticker
- $CCCC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 104
- Headquarters
- Watertown, United States
- Website
- www.c4therapeutics.com
C4 Therapeutics Metrics
BasicAdvanced
$381M
-
-$0.71
-
-
Price and volume
Market cap
$381M
52-week high
$5.17
52-week low
$1.69
Average daily volume
2.7M
Financial strength
Total debt to equity
0.23
Profitability
EBITDA (TTM)
-100.645
Gross margin (TTM)
72.19%
Net profit margin (TTM)
-282.22%
Operating margin (TTM)
-315.86%
Effective tax rate (TTM)
-0.13%
Revenue per employee (TTM)
$310,000
Management effectiveness
Valuation
Price to revenue (TTM)
12.248
Price to book
1.54
Price to tangible book (TTM)
1.54
Growth
Revenue change (TTM)
7.20%
Earnings per share change (TTM)
-57.26%
3-year revenue growth (CAGR)
16.62%
3-year earnings per share growth (CAGR)
-36.22%
What the Analysts think about C4 Therapeutics
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
Analyst projections of the future price of C4 Therapeutics stock.
Bulls say / Bears say
In Phase 1, cemsidomide produced a 53% overall response rate at the 100 µg dose, with some responses deepening over time. This early signal gives the lead programme a promising base for its larger trial. (C4 Therapeutics, Inc.)
Cemsidomide has shown T-cell activation in its Phase 1 study, while early results from the first two patients in the elranatamab combination supported T-cell expansion without signs of exhaustion. The 75 µg combination dose has cleared its first safety review and is moving into expansion. (C4 Therapeutics, Inc.)
C4T reported $274.7 million in cash and marketable securities at the end of September and expects this to fund operations through 2028. That should help it reach its planned 2027 clinical readouts without an immediate need to raise capital. (C4 Therapeutics, Inc.)
The key Phase 2 trial is single-arm, and initial response data are not expected until the second half of 2027. Investors must wait for a larger dataset to learn whether the encouraging early results hold up. (C4 Therapeutics, Inc.)
Grade 4 neutropenia occurred in about one-third of patients across the Phase 1 dose levels, creating a meaningful safety risk. The company says it was manageable, but tolerability will need to hold as treatment moves into larger studies. (Investing.com)
C4T has decided not to advance CFT8919 outside Greater China, citing the changing EGFR treatment landscape, capital priorities and clinical data to date. This removes a potential development path from its oncology pipeline beyond cemsidomide. (C4 Therapeutics, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
C4 Therapeutics Financial Performance
Revenues and expenses
C4 Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing C4 Therapeutics
Fund name | Fund size | $CCCC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.